FemBloc
DeviceTreatment with FemBloc for women who desire permanent birth control (female sterilization)
NCT Number: NCT03433911
Prospective, multi-center, international, non-randomized, two-arm study of subjects undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control). The FemBloc group total study duration will be approximately 65 months. The laparoscopic tubal sterilization (Control) group total study duration will be approximately 62 months.
Looking for future studies?
Notify Me21 year–45 year
Female
Interventional
Not applicable
New Horizons Clinical Trials, Chandler, Arizona, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment with FemBloc for women who desire permanent birth control (female sterilization)
Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
Time frame: 1-5 years
Safety: Incidence of short-term and long-term adverse events in each arm
Looking for future studies?
Notify MeFemasys Inc.
Industry
BLOC: Prospective Multi-Center Office Based Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception
Acronym: BLOC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05139121
Contraception
Mobile, Alabama, United States
View Trial DetailsNCT03067272
Contraception
New York, United States
View Trial DetailsNCT06664034
Cancer, Contraception
Brawley, California, United States
View Trial DetailsNCT05818254
Autoimmune Diseases, Connective Tissue Diseases
Chicago, Illinois, United States
View Trial Details